<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00211159</url>
  </required_header>
  <id_info>
    <org_study_id>OmegAD#1</org_study_id>
    <nct_id>NCT00211159</nct_id>
  </id_info>
  <brief_title>OmegAD (Omega-3 and Alzheimer's Disease)</brief_title>
  <official_title>Omega-3 Fatty Acid Treatment of 174 Patients With Mild to Moderate Alzheimer's Disease (OmegAD): a Randomized Double-blind Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <brief_summary>
    <textblock>
      Memory loss and difficulties with thinking associated with Alzheimer's disease (AD) may be
      due to a deficiency in the brain of a fatty acid named DHA. The aim of this trial is to see
      if dietary supplementation with a preparation, rich in DHA, will halt cognitive impairment in
      AD patients
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2000</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognition measured according to ADAS-cog, MMSE scales</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety, tolerability, blood pressure</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene expression</measure>
    <time_frame>2007-2018</time_frame>
    <description>mRNA expression and DNA methylation changes in blood leukocytes in relation to changes of plasma and cerebrospinal concentrations of omega-3 fatty acids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-response studies in relation to APOE4 status, to body weight and to gender</measure>
    <time_frame>2007-2018</time_frame>
    <description>Analysis of changes of plasma and cerebrospinal fluid concentrations of omega-3 fatty acids in relation to APOE4 status, body weight and gender, as well as to changes in ADAS-cog and MMSE as measures of cognition.</description>
  </secondary_outcome>
  <enrollment>204</enrollment>
  <condition>Alzheimer's Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPAX 1050TG</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Alzheimer's disease with MMSE 15-30, living in own homes, treated with
        stable dose of acetylcholine esterase inhibitor for &gt;3 months and remaining on that
        treatment for the study period

        Exclusion Criteria: Already treated with omega-3 fatty acids, NSAIDs, warfarin, being an
        alcohol abuser, suffering from serious concomitant disease or not having a caregiver
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tommy Cederholm, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uppsala University, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karolinska University Hospital Huddinge</name>
      <address>
        <city>Stockholm</city>
        <zip>S-141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Eriksdotter M, Vedin I, Falahati F, Freund-Levi Y, Hjorth E, Faxen-Irving G, Wahlund LO, Schultzberg M, Basun H, Cederholm T, Palmblad J. Plasma Fatty Acid Profiles in Relation to Cognition and Gender in Alzheimer's Disease Patients During Oral Omega-3 Fatty Acid Supplementation: The OmegAD Study. J Alzheimers Dis. 2015;48(3):805-12. doi: 10.3233/JAD-150102.</citation>
    <PMID>26402079</PMID>
  </reference>
  <results_reference>
    <citation>Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T, Basun H, Faxén-Irving G, Garlind A, Vedin I, Vessby B, Wahlund LO, Palmblad J. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol. 2006 Oct;63(10):1402-8.</citation>
    <PMID>17030655</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang X, Hjorth E, Vedin I, Eriksdotter M, Freund-Levi Y, Wahlund LO, Cederholm T, Palmblad J, Schultzberg M. Effects of n-3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. J Lipid Res. 2015 Mar;56(3):674-81. doi: 10.1194/jlr.P055418. Epub 2015 Jan 23.</citation>
    <PMID>25616438</PMID>
  </results_reference>
  <results_reference>
    <citation>Freund-Levi Y, Vedin I, Hjorth E, Basun H, Faxén Irving G, Schultzberg M, Eriksdotter M, Palmblad J, Vessby B, Wahlund LO, Cederholm T, Basu S. Effects of supplementation with omega-3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. J Alzheimers Dis. 2014;42(3):823-31. doi: 10.3233/JAD-132042.</citation>
    <PMID>24934544</PMID>
  </results_reference>
  <results_reference>
    <citation>Freund Levi Y, Vedin I, Cederholm T, Basun H, Faxén Irving G, Eriksdotter M, Hjorth E, Schultzberg M, Vessby B, Wahlund LO, Salem N Jr, Palmblad J. Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. J Intern Med. 2014 Apr;275(4):428-36. doi: 10.1111/joim.12166. Epub 2014 Jan 11.</citation>
    <PMID>24410954</PMID>
  </results_reference>
  <results_reference>
    <citation>Vedin I, Cederholm T, Freund-Levi Y, Basun H, Garlind A, Irving GF, Eriksdotter-Jönhagen M, Wahlund LO, Dahlman I, Palmblad J. Effects of DHA-rich n-3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One. 2012;7(4):e35425. doi: 10.1371/journal.pone.0035425. Epub 2012 Apr 24.</citation>
    <PMID>22545106</PMID>
  </results_reference>
  <verification_date>April 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>July 27, 2017</last_update_submitted>
  <last_update_submitted_qc>July 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2017</last_update_posted>
  <keyword>Alzheimer's disease</keyword>
  <keyword>Omega-3 fatty acid</keyword>
  <keyword>Dietary supplementation</keyword>
  <keyword>Cognition</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

